NewsBenzingaBelite Bio dépose une demande d’autorisation de mise sur le marché à Singapour, au Royaume-Uni et en Suisse pour Tinlarebant dans le traitement de la maladie de Stargardt de type 1 Belite Bio dépose une demande d’autorisation de mise sur le marché à Singapour, au Royaume-Uni et en Suisse pour Tinlarebant dans le traitement de la maladie de Stargardt de type 1 Benzinga 2026.10.14 20:04 (GMT+0) Open on Benzinga Other news MIIT and Seven Other Departments: Accelerate AI Implementation Across Product R&D, Design Simulation, Pilot Verification, and Production Operations Kanye West-linked address goes long ETH via Aave looping, withdrawing a total of 12,549.9 ETH Report: Microsoft's headcount declines for first time in a decade, down about 5,000 in FY2026 GMX proposal plans to use remaining Solana-side revenue for buybacks and introduce a 180-day unstaking waiting period Broadcom's M&A Strategy Is A Value Play (NASDAQ:AVGO) Crown Castle Inc. (CCI) Q3 2026 Earnings Call Transcript
MIIT and Seven Other Departments: Accelerate AI Implementation Across Product R&D, Design Simulation, Pilot Verification, and Production Operations
GMX proposal plans to use remaining Solana-side revenue for buybacks and introduce a 180-day unstaking waiting period
